Axel Le Cesne, MD

Head
International Department, Gustave Roussy Institute
Villejuif, Ile-de-France, France

Presentation(s):

• Paper 31 - THE TETRAVALENT DEATH RECEPTOR 5 AGONIST OZEKIBART (INBRX-109) IN CHONDROSARCOMA: RESULTS FROM THE RANDOMIZED, REGISTRATIONAL, PHASE 2 CHONDRAGON STUDY

  Friday, November 14, 2025
  8:30 AM - 10:00 AM EST

  Disclosure information not submitted.

• Paper 35 - A POOLED ANALYSIS OF PHASE 2 CLINICAL TRIALS IN ADVANCED CHORDOMA

  Friday, November 14, 2025
  10:30 AM - 12:00 PM EST

  Disclosure information not submitted.

• Paper 45 - LONG-TERM EFFICACY AND SAFETY OF VIMSELTINIB IN PATIENTS (PTS) WITH TENOSYNOVIAL GIANT CELL TUMOR (TGCT): RESULTS FROM THE MOTION PHASE 3 TRIAL

  Friday, November 14, 2025
  2:30 PM - 3:30 PM EST

  Disclosure information not submitted.